definiens: shall mean and collectively include all inventions relating to the TSAR Technology as developed in the laboratories of Dr. Dana Fowlkes and Dr. Brian Kay at the University, which ( a ) were in existence on the Effective Date of this Agreement or which are made at any time in accord with or pursuant to the Research Agreements ; and ( b ) which are legally and/or beneficially owned, and/or controlled by University and/or which pursuant to University 's employment contract or policy covering University 's scientific staff are obligated to be assigned to University . TSAR Technology, based on or resulting from data developed in the laboratories of Dr. Dana Fowlkes and Dr. Brian Kay, shall also mean and collectively include the identification, production, manufacture and/or utilization of ( a ) TSARs which includes any proteins, polypeptides and/or peptides, having specific binding affinity for any of a wide variety of ligands or portions thereof, said ligands, including but not limited to a chemical group, an ion, a metal, a synthetic organic compound, a bioorganic compound, an inorganic compound, a protein or peptide, a nucleic acid, a carbohydrate, a lipid, a fatty acid, a viral particle, a membrane vesicle, a cell wall component, or any portion 6 of any of the above, identified by a process encompassing screening a library of vectors expressing a plurality of semi - random or random oligonucleotide sequences to identify those encoding a protein, polypeptide or peptide having specificity for a ligand of choice ; ( b ) nucleotide sequences encoding TSARs ; ( c ) vectors and/or libraries of vectors containing nucleotide sequences encoding TSARs ; and ( d ) transformed cells containing the vectors encoding TSARs . The TSARs shall include both ( a ) unifunctional proteins, polypeptides and/or peptides having a binding domain with affinity for a ligand ; and ( b ) heterofunctional proteins, polypeptides and/or peptides having a binding domain with affinity for a ligand and one or more biologically or chemically active effector domains, in which the binding domain and the effector domain can optionally be joined by a linker domain which is either stable or susceptible to cleavage